Skip to search formSkip to main contentSkip to account menu

KOS-1584

Known as: Epothilone KOS-1584 
A second-generation epothilone with potential antineoplastic activity. Epothilone KOS-1584 binds to tubulin and induces microtubule polymerization… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Epothilones
Microtubule Process

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
From bacteria to antineoplastic: epothilones a successful history.
Malignancies are a major cause of morbidity and mortality worldwide. Cancer is a cell disease, characterized by a deviation of… 
2012
2012
Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors
PurposeFirst-in-man study of KOS-1584, a second generation epothilone.MethodsPatients with advanced solid malignancies received… 
Review
2010
Review
2010
MICROTUBULE: A NOVEL TARGET FOR CANCER THERAPY
For cancer therapy, microtubule network is an attractive cellular target. Main component of cell cycle is mitotic stage… 
Review
2009
Review
2009
Epothilones: better or more of the same?
Agents that interfere with microtubule structure and function continue to play a major role in cancer treatment. The vinca… 
Review
2008
Review
2008
Ixabepilone in Metastatic Breast Cancer: Complement or Alternative to Taxanes?
Targeting the microtubule is a successful strategy in the treatment of solid tumors. There is an ongoing effort to develop newer… 
Review
2008
Review
2008
Preclinical investigations with epothilones in breast cancer models.
The epothilones constitute a novel class of microtubule inhibitors that act like the taxanes by hyperstabilizing tubulin… 
2007
2007
Phase I trial of KOS-1584 (a novel epothilone) using two weekly dosing schedules
2571 Background: KOS-1584 is an epothilone with increased potency and improved pharmacologic profile (enhanced water solubility… 
2007
2007
Optimization of the phase 2 dose of KOS-1584 (a novel, synthetic epothilone) via weekly administration
A286 Background: KOS-1584 is a potent synthetic epothilone with an attractive pharmacologic profile (water soluble, excellent… 
2006
2006
First-in-human phase I trial of a novel epothilone, KOS-1584.
2003 Background: KOS-1584 (9,10-didehydroepothilone D) was discovered as part of a screening program to develop a new generation… 
2006
2006
Phase I trial of a novel epothilone, KOS-1584, using a weekly dosing schedule.
2041 Background: Several epothilones are progressing through phase 1-3 clinical trials treating solid tumor malignancies. KOS… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)